ft 08 oct 93 intern compani news roch see profit growth 9 month sale rise 11 roch surpass merck us becom world highli valu pharmaceut group report 11 per cent rise sale first nine month year sfr10 7bn dollar 7 1bn figur reflect 18 per cent increas sale third quarter doubl growth rate achiev first second quarter basl base group said expect good increas sale fourth quarter ad bar extraordinari circumst anoth signific increas group profit expect current busi year roch share wide held genussschein dividend right certif close held bearer doubl valu past year buck gener trend investor lose enthusiasm pharmaceut share increas polit pressur drug price yesterday midday price valu roch sfr52 3bn wednesday close new york merck largest us drug group valu dollar 34 35bn sfr48 9bn glaxo uk stand pound 19 9bn dollar 30bn roch said divis contribut growth sale revenu pharmaceut divis account half total soar 29 per cent sfr1 9bn quarter group said drug sale affect much competitor polit action high price countri product heavili orient hospit sector competit forc long strong us germani anoth countri govern pressur drug price step emphasi doctor prescript rather hospit purchas roch point sale figur flatter third quarter weaken dollar swiss franc said new product aurorix anti depress inhibac treat high blood pressur neupogen prevent chemotherapi relat disord show particularli high growth rate diagnost divis 19 per cent jump sale third quarter sfr432m mainli due good perform us servic laboratori sandoz swiss pharmaceut group hope doubl digit profit growth 1993 doubl digit growth like certainli scale last year mr daniel wagnier new chief oper offic said